[go: up one dir, main page]

MX2015009696A - Composiciones estables que comprenden heparinoide, anestesico de accion aguda y regulador de ph. - Google Patents

Composiciones estables que comprenden heparinoide, anestesico de accion aguda y regulador de ph.

Info

Publication number
MX2015009696A
MX2015009696A MX2015009696A MX2015009696A MX2015009696A MX 2015009696 A MX2015009696 A MX 2015009696A MX 2015009696 A MX2015009696 A MX 2015009696A MX 2015009696 A MX2015009696 A MX 2015009696A MX 2015009696 A MX2015009696 A MX 2015009696A
Authority
MX
Mexico
Prior art keywords
heparinoid
acute
buffer
acting anesthetic
compositions
Prior art date
Application number
MX2015009696A
Other languages
English (en)
Inventor
C Lowell Parsons
Original Assignee
Urigen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Urigen Pharmaceuticals Inc filed Critical Urigen Pharmaceuticals Inc
Publication of MX2015009696A publication Critical patent/MX2015009696A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Anesthesiology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen métodos mejorados para preparar composiciones incluyen un heparinoide, un anestésico de acción aguda y un regulador de pH; estos métodos resultan en composiciones en las que el heparinoide y el anestésico de acción aguda son por lo menos 90% estables durante un año; las composiciones preparadas mediante estos métodos y que tienen tales propiedades de estabilidad mejorada también se describen, así como métodos de uso de estas composiciones para tratar, aliviar o evitar trastornos del tracto urinario inferior tal como la cistitis.
MX2015009696A 2013-01-28 2014-01-28 Composiciones estables que comprenden heparinoide, anestesico de accion aguda y regulador de ph. MX2015009696A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361757592P 2013-01-28 2013-01-28
PCT/US2014/013352 WO2014171986A1 (en) 2013-01-28 2014-01-28 Stable compositions comprising heparinoid, acute-acting anesthetic, and buffer

Publications (1)

Publication Number Publication Date
MX2015009696A true MX2015009696A (es) 2016-03-31

Family

ID=51731742

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015009696A MX2015009696A (es) 2013-01-28 2014-01-28 Composiciones estables que comprenden heparinoide, anestesico de accion aguda y regulador de ph.

Country Status (13)

Country Link
US (1) US20150359816A1 (es)
EP (1) EP2948154A4 (es)
JP (2) JP2016517390A (es)
KR (1) KR20160008496A (es)
CN (1) CN105263503A (es)
AU (2) AU2014254472A1 (es)
BR (1) BR112015018047A8 (es)
CA (1) CA2899636C (es)
IL (1) IL240194B (es)
MX (1) MX2015009696A (es)
SG (1) SG11201505853RA (es)
WO (1) WO2014171986A1 (es)
ZA (1) ZA201505814B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10117847B2 (en) 2015-12-04 2018-11-06 Ventis Pharma Extended duration local anesthetic formulation
CA3090767A1 (en) 2017-02-27 2018-08-30 Urigen N.A. Treatment of lower urinary tract epithelium with glucagon like peptide 2
CA3061891A1 (en) 2017-04-12 2018-10-18 Urigen Pharmaceuticals, Inc. Article of manufacture comprising local anesthetic, buffer, and glycosaminoglycan in syringe with improved stability
ES2775673T3 (es) * 2017-05-12 2020-07-27 Farco Gmbh Composición para el tratamiento de enfermedades inflamatorias del tracto urogenital que contiene sulfato de condonita (4,5 mg/ml), ácido hialurónico (16 mg/ml) y tampón de fosfato (pH 6,1 a 7,9) con mayor estabilidad de almacenamiento para tratar la cistitis
EP3415163B1 (de) * 2017-06-13 2023-02-22 Farco-Pharma GmbH Zusammensetzung mit lokalanästhetischer wirkung und deren verwendung
EP3958873B1 (en) * 2019-04-26 2023-11-22 TCM Biotech International Corp. Pharmaceutical composition for prevention of recurrent urinary tract infection
TWI887239B (zh) * 2019-05-17 2025-06-21 日商半導體能源研究所股份有限公司 發光元件、發光裝置、電子機器及照明裝置
CA3147731A1 (en) 2019-07-18 2021-01-21 C. Lowell Parsons Alkalization of urinary bladder wall prior to treatment with intravesical heparin and alkalinized lidocaine to enhance relief of bladder pain symptoms
CN115814099B (zh) * 2022-12-19 2024-04-26 成都蓉生药业有限责任公司 一种人凝血因子ix的干热处理稳定剂及其制剂与制备方法
MX2023012862A (es) * 2023-10-27 2023-11-09 Mar Mariana Guerrero Composicion topica de agentes esclerosantes en portadores acuosos.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5603695A (en) * 1995-06-07 1997-02-18 Erickson; Kim Device for alkalizing local anesthetic injection medication
AU2005209322B2 (en) * 2004-01-28 2011-05-19 The Regents Of The University Of California Novel interstitial therapy for immediate symptom relief and chronic therapy in interstitial cystitis
JP5731729B2 (ja) * 2005-01-14 2015-06-10 ウーリゲン、インコーポレイテッド 下部尿路障害を治療するためのキット及び改良された組成物
WO2007073397A1 (en) * 2005-12-19 2007-06-28 Urigen, Inc. Kits and improved compositions for treating lower urinary tract discorders
US8357795B2 (en) * 2008-08-04 2013-01-22 Allergan, Inc. Hyaluronic acid-based gels including lidocaine
CA2771110C (en) * 2009-08-13 2019-02-26 Singularis, Inc. Prg4 treatment for interstitial cystitis
SG10201809955SA (en) * 2011-01-06 2018-12-28 Lowell Parsons C Method for manufacturing composition comprising local anesthetic, heparinoid, and buffer
US9486747B2 (en) * 2014-08-12 2016-11-08 The Curators Of The University Of Missouri Nanocomposite membranes with advanced antifouling properties under visible light irradiation

Also Published As

Publication number Publication date
EP2948154A1 (en) 2015-12-02
WO2014171986A1 (en) 2014-10-23
AU2018247284A1 (en) 2018-11-01
KR20160008496A (ko) 2016-01-22
BR112015018047A8 (pt) 2019-11-05
JP2019006783A (ja) 2019-01-17
BR112015018047A2 (pt) 2017-07-18
JP2016517390A (ja) 2016-06-16
CA2899636A1 (en) 2014-10-23
AU2014254472A1 (en) 2015-08-20
CA2899636C (en) 2021-05-25
IL240194B (en) 2021-12-01
SG11201505853RA (en) 2015-08-28
EP2948154A4 (en) 2016-09-14
ZA201505814B (en) 2016-11-30
IL240194A0 (en) 2015-09-24
US20150359816A1 (en) 2015-12-17
CN105263503A (zh) 2016-01-20

Similar Documents

Publication Publication Date Title
MX2015009696A (es) Composiciones estables que comprenden heparinoide, anestesico de accion aguda y regulador de ph.
PH12018501226A1 (en) Methods for treating huntingtons disease
CA2865011C (en) Methods and compositions for treating huntington's disease
MX2019015578A (es) Metodos para tratar la enfermedad de huntington.
IN2015DN01156A (es)
MX2019015580A (es) Metodos para tratar la enfermedad de huntington.
MX2017016424A (es) Compuestos para su uso en el tratamiento de trastornos neuromusculares.
PH12016502066A1 (en) Methods of treating bladder cancer
MX2016004678A (es) Composiciones para el tratamiento del cancer.
MX2020009223A (es) Anticuerpos anti-fgfr2iiib afucosilados.
SG10201809290SA (en) Compositions and Methods to Treating Hemoglobinopathies
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
MX356368B (es) Profarmacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
MX2016002794A (es) Compuestos antiproliferativos.
NZ720769A (en) Anti-siglec-8 antibodies and methods of use thereof
MX339201B (es) Compuestos de sulfonamida y métodos para elaborarlos y usarlos.
MX2016005760A (es) Inhibidores de glucogeno sintasa cinasa 3 (gsk-3).
MX2015011783A (es) Metodos para tratar tumores solidos pediatricos.
MX2014008705A (es) Compuestos tricíclicos de sulfona y métodos para elaborarlos y utilizarlos.
MX366368B (es) Metodos para el cuidado oral prebiotico usando un sacarido.
PH12018500315A1 (en) Fumagillol heterocyclic compounds and methods of making and using same
MX356755B (es) Compuestos de tipo fumagilol y metodos para su elaboración y uso.
EP4289820A3 (en) Compounds for use in treating alzheimer's disease in apoe4+/+ patients
MY191932A (en) Chitosan-derived compositions
MX2016009241A (es) Metodos para reducir el mal olor y las bacterias.